Thalidomide and rituximab in Waldenstrom macroglobulinemia.

SP, Treon; JD, Soumerai; AR, Branagan; ZR, Hunter; CJ, Patterson; L, Ioakimidis; FM, Briccetti; M, Pasmantier; H, Zimbler; RB, Cooper; M, Moore; J 2nd, Hill; A, Rauch; L, Garbo; L, Chu; C, Chua; SH, Nantel; DR, Lovett; H, Boedeker; H, Sonneborn; J, Howard; P, Musto; BT, Ciccarelli; E, Hatjiharissi; KC, Anderson

doi:10.1182/blood-2008-04-150854

Public

Thalidomide and rituximab in Waldenstrom macroglobulinemia.

Shared by NobleBlocks on Aug 19, 2008 • 12:00 AM UTC

Authors:

Treon SP

Soumerai JD

Branagan AR

Abstract

Thalidomide enhances rituximab-mediated, antibody-dependent, cell-mediated cytotoxicity. We therefore conducted a phase 2 study using thalidomide and rituximab in symptomatic Waldenstrom macroglobulinemia (WM) patients naive to either agent. Intended therapy consisted of daily thalidomide (200 mg fo...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!